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1. SUMMARY  
 
Title: Diagnosis and treatment of bulimia 
 
Author: Ana Blazenka Zoric  
 
 An eating disorder is a type of psychiatric illness where the behavioural pattern of an 
individual, with regards to eating, negatively affects his or her mental and physical health. 
One of these disorders is bulimia nervosa, also known simply as bulimia. Bulimia is 
characterized by the classic cycle of binge eating followed by purging. This diagnosis in itself 
can be challenging to make because it involves careful consideration of other disorders and 
fulfilment of certain criteria according to DSM. Although many different theories exist about 
the etiology of the disease, no agreement has still been reached in the scientific community. 
Both biological factors, in terms of neurotransmitters and hormones, as well as social factors, 
specifically unique to each individual, seem to play a role in the etiology. Treatment 
primarily involves psychotherapy however, pharmacologic therapy has also been proven to 
be beneficial. Of all the different drugs available for treatment of the disease, current 
psychopharmacological research has focused on the selective serotonin reuptake inhibitors 
(SSRIs). Some researchers have also claimed positive outcomes in light therapy. Bulimia is a 
serious disorder and should not be taken lightly. Just like any other serious condition, it 
should be approached with the same intensity for diagnosis and treatment.  
 
 
Key words: bulimia – binge eating – purging – social idealizations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. SAŽETAK 
Naslov: Dijagnoza i liječenje bulimije 
 
Autor: Ana Blaženka Zorić  
 
 Poremećaj prehrane je tip psihičke bolesti kod kojih težište ponašanja, s obzirom na 
prehranu, negativno djeluje na fizičko i psihičko zdravlje pacijenata. Jedan od tih poremećaja 
je bulimija nervosa, isto tako jednostavnije poznata kao bulimija. Bulimija je opisana kao 
klasični ciklus prejedanja i pražnjenja (povraćanja). Dijagnoza sama po sebi može biti 
izazovna zato što uključuje pažljivo razmatranje drugih poremećaja i ispunjenje posebnih 
kriterija po DSM-u. Iako mnogo teorija postoje o etiologiji bolesti, nije došlo do ujedinjenosti 
u znanstvenim krugovima. Biologijski čimbenici u vezi neurotransmitera i hormona, a isto 
tako i socijalni čimbenici specifični za pojedinog pacijenta, igraju veliku ulogu u etiologiji. 
Liječenje prvenstveno uključuje psihoterapiju, ali i farmakološku terapiju koja je dokazano 
vrlo korisna. Od svih različitih lijekova dostupnih za liječenje bolesti, psihofarmakološka 
dostupna istraživanja su fokusirana na selektivne inhibitore ponovne pohrane serotonina 
(SSRIs). Neki znanstveni istrarživaći također istražuju pozitivne rezultate u svjetlosnoj 
terapiji. Bulimija je ozbiljni poremećaj i ne smije se uzeti olako. Isto kao bilo koje ozbiljno 
stanje mora joj se priči sa istim intenzitetom za dijagnozu i liječenje.   
  
 
Ključne riječi: bulimija – prejedanje – povraćanje – socijalna idealizacija 
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3. INTRODUCTION  
 
 
 Taking a look at human history it is evident that eating disorders have existed for a 
long time. The classic cycle of binging and purging, as seen in bulimia, was a habitual 
practice among the elite members of society during the roman period. Individuals who 
attended all day banquets would purge in order to make room for more food. This idea of 
purging the contents of the stomach was even considered therapeutic by some societies. In 
ancient Egypt, for example, physicians would actually recommend purging once a month for 
three days in order to preserve health. In a similar manner, during the medieval ages, 
purgation was used as a remedy to treat a variety of conditions. With all of these historical 
misconceptions about the so-called benefits of purging, illnesses like bulimia seem to have 
been inevitable in the present. The first published description of bulimia as a disorder was 
made in the year 1979 by Professor Gerald Francis Morris Russell, a British psychiatrist who 
worked at the Royal Free Hospital and the Maudsley Hospital in London. According to 
Russell, patients who overate were exhibiting a "morbid fear of becoming fat” and as a result, 
purged afterwards. In addition to this, he noted the seriousness of the disease especially after 
seeing that it can be accompanied by depression and suicide. As a result of Professor 
Russell’s contributions to the identification of bulimia as a mental disorder in itself, in the 
year 1980 bulimia nervosa appeared in the DSM-III. This disorder truly has an appropriate 
name as the term bulimia comes from the Greek words βουλιμία boulīmia meaning “ravenous 
hunger” while nervosa translates to nervous. This disease of “nervous ravenous hunger” 
seems to have a complicated etiology that is still not fully understood yet, regardless of that, 
appropriate treatment options are available with varying success rates. The main treatments 
given to those suffering with bulimia nervosa are psychopharmacological and psychosocial 
treatments. Of the psychopharmacological therapies, cognitive behavioural therapy, family-
based treatment, and interpersonal psychotherapy have shown promising results for patients 
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with bulimia. Possible combinations of one of these therapies with pharmacotherapy is also 
promising however, trials performed to show the effectiveness of this mode of treatment have 
not proven to be exceptionally powerful as opposed to what was originally suggested. Out of 
the possible pharmacotherapy options, antidepressants seem to predominate with SSRIs being 
the most popular choice. Beginning any of the above mentioned treatments is important for 
patients with bulimia because this disease has such a huge impact on the daily lives of these 
individuals. The quality of life of these patients is severely affected in addition to the 
numerous complications that they face as a result of the cycle of binging and purging. Like 
with most mental disorders, treatment of bulimia is a chronic and challenging process that the 
patient must accomplish together with their psychiatrist. 
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4. EPIDEMIOLOGY 
 
 
 The prevalence of bulimia within a certain population will differ between Western 
and non-Western countries. Prevalence rates for bulimia in male subjects in Western 
countries ranges from 0% to 2.1% while in female subjects in Western countries it ranges 
from 0.3% to 7.3%. On the other hand, prevalence rates in non-Western countries range from 
0.46% to 3.2% in female subjects (Makine et al., 2004). There are many theories as to the 
exact cause of this difference in prevalence including differences in fundamental political 
ideologies and cultural sociological aspects of those countries. Gender, on the other hand, 
seems to play an important role when it comes to the incidence of bulimia. According to 
Barker, bulimia is nine times more likely to occur in women than men (Barker, 2003). As for 
the age of onset of this disease, there seems to be some inconsistencies when it comes to 
studies on time trends. According to Gelder, Mayou and Geddes bulimia is prevalent between 
1-2% of women aged 15-40 years (Gelder et al., 2005). Taking a look at this disease from the 
pediatric perspective, the lifetime prevalence of bulimia is between 0.9% and 3%,with an 
older age of onset of 16 to 17 years (Campbell & Peebles, 2014). Compared to other eating 
disorders like anorexia, the risk of lifetime suicidality and suicide attempts are much higher. 
On the other hand, mortality rates in bulimia are estimated to be approximately 2% 
(Campbell & Peebles, 2014). Economic status is another key contributor as it has been shown 
that girls from the lowest income bracket studies are 153% more likely to be bulimic than 
girls from the highest income bracket (Nauert, 2009). In conclusion, bulimia occurs more 
frequently in the female population of developed countries, specifically in those of lower 
economic status.   
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5. ETIOLOGY  
 
 
 The exact cause of bulimia has yet to be agreed upon in the scientific community. 
However, what is accepted is that the etiology of this disease has many components to it that 
can broadly be classified as biological, psychological, or social.  
 
 Biological Factors: 
 
-Neurotransmitters- 
Dopamine 
 Some studies have suggested that impaired dopaminergic transmission may be linked 
to the development of eating disorders, particularly bulimia. As a brief review, dopamine is a 
catecholamine neurotransmitter and is produced by neurons in the brain that have cell bodies 
in the substantia nigra. Non-striatal dopamine is made in the kidneys by proximal tubule 
cells. However, this dopamine is thought to act locally and is therefore, of minimum 
importance for this topic. To count there are five dopamine receptors, each with different 
effects and locations throughout the body. In addition, there are five important dopaminergic 
pathways in the brain. Of these five, the medullary-periventricular pathway is suspected in 
eating behaviour. It consists of neurons in the motor portion of the vagus nerve. Another 
important pathway is the mesolimbic-mesocortical pathway. It projects from the substantia 
nigra to the limbic system and neocortex and is involved in the reward system and is 
implicated in addiction. More research is definitely needed in order to discover if any 
relationship exists between these pathways and bulimia.  What has been discovered to date, 
thanks to the work of Bartley G. Hoabel, is that striatal dopamine has a vital importance in 
feeding behaviours as well as the disordered eating behaviours as seen in bulimia. This is also 
evident with preclinical models of bulimia-like eating behaviours that are associated with 
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changes in striatal dopamine and dopamine receptor measures. In addition, emerging clinical 
research also suggests that striatal dopamine abnormalities exist in individuals with bulimia 
(Broft et al., 2011). What is important to note is that the precise relationship between these 
findings and the etiology of bulimia still remains unclear and definitely warrants further 
investigation.  
According to a study performed by Dr. Frieling and his colleagues, impaired 
dopaminergic transmission is suspected to contribute to the etiology of anorexia and bulimia. 
To prove this, they examined whether the expression of dopaminergic genes is altered in 
people suffering from these two diseases. They hypothesized that this alteration can be 
explained by changes in the promoter specific DNA methylation of genes. By examining the 
blood of patients with anorexia and bulimia, and that of healthy controls for the expression 
and the promoter specific DNA methylation of the dopamine transporter (DAT) along with 
the D2 (DRD2) and D4 receptor (DRD4) gene, they were able to draw conclusions about the 
dysregaltion of dopamine. Anorexia and bulimia patients showed an elevated expression of 
DAT mRNA (messenger RNA) and a downregulation of the DRD2 expression. Yet, this 
upregulation of the DAT gene was accompanied by a hypermethylation of the gene’s 
promoter (Frieling et al., 2009). This study suggests that patients suffering from bulimia have 
a disturbed expression of dopaminergic genes.  
 
Serotonin 
 Serotonin is a monoamine neurotransmitter that is derived from tryptophan. It is 
thought to be a contributor to the feelings of well-being, happiness, and satiation. In this 
being said, some researchers believe that binge behaviour of patients with bulimia actually 
stems from a chemical imbalance in the brain due to low serotonin levels (Hirst, 1998). 
Experiments performed on laboratory animals showed that when serotonin is released into 
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either the ventromedial hypothalamus or the lateral hypothalamus that eating is stopped and 
starvation results. When serotonin levels are reduced the opposite happens and obesity 
ensues. Although this study was performed on animals, it still provides insight into possible 
mechanisms of serotonin involvement in the etiology of bulimia. Another study, performed 
by Jimerson and his colleagues supports this idea. In this study, cerebrospinal fluid (CSF) 
neurotransmitter metabolite levels were examined in patients suffering from bulimia with a 
history of binge eating and in healthy controls. The results of the study showed that bulimic 
patients had significantly lower CSF concentrations of 5-hydroxyindoleacetic acid and 
homovanillic acid, metabolites of the neurotransmitters (Jimerson et al., 1992). However, 
although these past studies implicate decreases in serotonin, that is not the only abnormality 
that can be found within the serotonin system. More recent studies were able to pin point a 
clearly picture of these alterations. According to one study, reduced central 5-HT transporter 
availability was found in women with bulimia (Tauscher et al., 2001) while another study 
showed reduced central 5-HT transporter availability in those who have recovered from 
bulimic anorexia (Bailer et al., 2011). In a similar manner, reduced 5HT2a receptor binding 
(in subgenualcingulate, mesial temporal, and parietal cortical regions) in women recovered 
from bulimia was concluded by a study performed by Bailer and colleagues (Bailer et al., 
2004). All of these different studies clearly demonstrate that serotonergic dysregulation must 
play a role in the etiology of bulimia.  
 
-Hormones- 
Estrogen  
 Since eating disorders are more prevalent in females than in males it is safe to assume 
that perhaps female sex hormone signalling may have something to do with the etiology of 
the disease. According to some experiments that were performed on laboratory animals, it has 
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been found that estrogen inhibits feeding and in that way affects feeding behaviour (Geary, 
2001). Other supporting evidence that is found in humans is that the occurrence of menstrual 
disturbances is increased in bulimic women (Nilsson et al., 2004). One specific study 
examined the possible role of the estrogen receptor β (ER β) variants and the relationship 
with bulimia. The gene for ER β is located on chromosome 14q, a region that was recently 
identified to meet the criterion for genome-wide suggestive linkage with bulimia. Although 
one German study did not provide evidence for an association between bulimia and ER β 
polymorphism (Rosenkranz et al., 2011), Nilsson’s study indicated that there is a possible 
role of ER β polymorphisms in the etiology of bulimia as they are located in the 3’UTR and 
could affect mRNA stability. Therefore, the ER β  most likely does play a role in the etiology 
of disease in bulimic patients.  
 
Psychological Factors: 
Thoughts, feelings and other cognitive characteristics that affect the behaviour and 
functions of the human mind seem to play a role in the etiology of bulimia. By taking a closer 
look at the binge-purge cycle through a psychoanalytical view, one can better understand 
bulimia from this perspective. According to Freud, in his letters to Fliess in 1899, 
psychogenic vomiting is an oral impregnation fantasy. He defined the self-punishing aspects 
of vomiting along with their function as a drive-defense compromise formation. From a 
Freudian or classical perspective, eating has become erotically appealing and bulimia is 
interpreted as representing a displacement and regression from genital wishes (Chassler, 
1997). From an object relations perspective, bulimia has been understood as the semi-
symbolic equivalent of the oral mother (Sperling, 1949), a concrete expression of the 
introjection-projection struggles of early infancy (Jessner & Abse, 1960), and traced to a 
developmental arrest at the earliest stage of transitional object development (Sugarman & 
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Kurash, 1982). Other research suggests that anorexia and bulimia are connected to 
attachment, in particular a disrupted attachment behavioural system (Armstrong & Roth, 
1989). According to one study performed by Chassler, a connection exists between anorexia 
and bulimia and early childhood attachment relationships as conceptualized by John 
Bowlby’s attachment theory. The findings of this study suggest that patients with anorexia 
and bulimia perceive a more disrupted attachment history in terms of both the nature and the 
quality of their attachments to primary caretakers. More specifically, results indicated that 
attachment figures were experienced as untrustworthy, unloving, or rejecting; aversive forms 
of parental discipline were predominantly used; peer relationships and support was poor; and 
intense feelings of shame, guilt, and being unwanted was linked to the diseases. The results of 
this study support the theory that one of the precursors to anorexia and bulimia may lie within 
family relationships (Chassler, 1997). 
 
Social Factors: 
 The media’s portrayal of the ideal “thin” body shape is thought to be a contributor to 
the etiology of bulimia. According to Fairburn et al.’s cognitive behavioural model, it is this 
idea, coupled with low self-esteem, which leads individuals to become extremely concerned 
with weight and shape and as a result, practice rigid and inflexible dietary rules. When there 
is an eventual “slip” of this diet it is the cognitive distortion that leads the individual to binge. 
In hopes of counteracting this perceived loss of control, the individual purges (Fairburn & 
Beglin, 1990). The pattern repeats itself over and over again producing a negative cycle in 
that patient’s life. This cognitive behavioural model is considered to be the gold standard for 
the etiology of bulimia however, another theory also exists. According to Byrne and Mclean, 
it is the drive for thinness that is the major cause of purging as a way of controlling weight. 
As a result, the individual is vulnerable to binging and in this way they argue that it is in fact 
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a purge-binge cycle (Byrne & Mclean, 2002). Both theories share the common underlying 
factor of society’s unrealistic thin idealization.  
 
Overlap of Genetic and Environmental Factors: 
Familial Aggregation 
 Although few studies have been done to examine the etiology of bulimia in terms of 
both genetic and environmental factors, those that were provide suggestive evidence of 
familial aggregation. By performing twin studies in the past thirty years, a definite 
relationship has been established between genetics and the etiology of eating disorders. For 
example, the heritability of bulimia was found to range from 28% to 83% (Peterson et al., 
2015). One specific study that was performed attempted to find the relationship between the 
patterns of SIV and the incidence amongst twins. As a side note, SIV is an eating disorder 
symptom that can be observed in bulimia and anorexia. However, as previously mentioned, it 
is the most reliably assessed behavioural feature of bulimia. This study, performed by Dr. 
Peterson and her colleagues, assessed SIV initiation and progression. The results showed that 
genetic factors that influenced liability to SIV progression were shared with SIV initiation 
however; a small proportion of liability to SIV progression was attributed to environmental 
factors that were unique to SIV progression and not shared with initiation. In other words, 
genetic factors play an important role for initiation yet; environmental factors are more 
responsible for progression. In a similar way, another study performed by Wade and 
colleagues suggested that individual-specific environmental factors are important in the 
progression to bulimia once binge eating is initiated (Wade et al., 2000). What can be 
concluded by these studies is that genetic vulnerability to thin ideal internalization might set 
the stage for a chain reaction increasing the risk for SIV initiation and progression yet; it is 
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the environmental factors that influence the transition to regular behaviour (Peterson et al., 
2015).  
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6. CLINICAL PICTURE AND DIAGNOSIS 
 
 
 Bulimia commonly has an onset after puberty till about the age of forty. It is thought 
to commence in adolescence where the binge eating frequently begins during or after an 
episode of dieting to lose weight (DSM-5). This episode of binge eating can be defined as 
eating, in a discrete period of time, an amount of food that is definitely larger than most 
individuals would eat in a similar period of time under similar circumstances (DSM-5). The 
diagnosis of bulimia should be considered in these patients who in addition, meet all the 
specific criteria for the disease. Essentially, there are three fundamental features of bulimia: 
recurrent episodes of binge eating (Criterion A), recurrent inappropriate compensatory 
behaviours to prevent weight gain (Criterion B), and self-evaluation that is unduly influenced 
by body shape and weight (Criterion D). In order to make the diagnosis of bulimia, the binge 
eating and inappropriate compensatory behaviours must occur at least once per week for 
three months (Criterion C) (DSM-5). These compensatory behaviours include self-induced 
vomiting, misuse of laxatives, diuretics, or other medications; fasting; or excessive exercise. 
 When making the diagnosis of bulimia it is also important to specify severity of the 
disease. The level of severity correlates to the frequency of inappropriate compensatory 
behaviours but may be increased to reflect other symptoms and the degree of functional 
disability (DSM-5). Mild disease is characterized by 1-3 episodes of inappropriate 
compensatory behaviours per week. Moderate disease has an average of 4-7 episodes of 
inappropriate compensatory behaviours per week. Sever disease has an average of 8-13 
episodes of inappropriate compensatory behaviours per week. Finally, patients suffering from 
extreme disease show an average of 14 or more episodes of inappropriate compensatory 
behaviours per week. 
 Identifying patients that may have bulimia can be a challenging process for 
physicians. In saying so, there are some physical signs that are helpful to look for. However, 
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some of these signs are similar to those seen in anorexia and that is why it is important to 
differentiate between the two diseases. Patients with bulimia may present with: lethargy, 
complaints of feeling bloated, constipation, abdominal pain, heart conduction abnormalities, 
irregular menstruation, tetany, and even occasional swelling of hands and feet (Collier et al., 
2009). Other specific problems related to purging include: metabolic alkalosis, 
hypochloraemia, hypokalaemia, metabolic acidosis (if laxative use), other electrolyte 
abnormalities, esophageal erosions, esophageal/gastric perforation, gastric/duodenal ulcers, 
pancreatitis, dental erosion, calluses on the back of the hands (Russell’s sign) and 
leucopenia/lymphocytosis (Semple & Smyth, 2009). There are also some associated features 
that can support the diagnosis. For example, individuals with bulimia are typically within the 
normal weight or overweight range with a BMI of > 18.5 and <30 in adults (DSM-5).  
 In addition to examining the physical signs and symptoms, it is also important to 
examine the psychological health of the patient. Self-esteem has been shown to be a 
contributing factor in the etiology of bulimia. In saying so, one study found that women who 
are high in perfectionism and who consider themselves overweight exhibit bulimic symptoms 
only if they have low self-esteem (i.e., if they doubt they can attain their high body 
standards). On the other hand, high self-esteem women with the same diathesis-stress 
conditions are less likely to exhibit bulimic symptoms (Vohs et al., 1999). Therefore, a 
patient’s self esteem level can also help the physician when considering a diagnosis of 
bulimia. In a similar manner, perfectionism seems to play a role as well in bulimic 
symptomatology. 
Additional questionnaires can be given to patients to act as screening tools for eating 
disorders. An example of this includes the SCOFF questions which are usually used in 
primary care. They have a low sensitivity yet; have still been proven to be useful. A score of 
at least 2 (meaning 2 yes answers) indicates that further more detailed history is indicated 
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before considering treatment or referral. Some of the SCOFF questions include: do you make 
yourself sick because you feel uncomfortably full, do you worry you have lost control over 
how much you eat, and do you believe yourself to be fat when others say you are too thin? 
(Semple & Smyth, 2009). Early identification of disease is very important for treatment 
success in patients with bulimia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
7. DIFFERENTIAL DIAGNOSIS 
  
 
 There are a number of diseases that can mimic bulimia and should be considered as a 
differential diagnosis. Out of these conditions, anorexia is usually the most closely-related to 
bulimia, specifically the binge-eating/purging type. In general, anorexia is an eating disorder 
that is characterized by low weight, fear of gaining weight, a strong desire to be thin, and 
food restriction. Individuals who have anorexia are underweight with a BMI that is usually in 
the range of 17- <15 depending on the severity of disease. This is one of the major 
differences between the two diseases because patients with bulimia, as previously stated, are 
not underweight. According to DSM-5, individuals whose binge-eating behaviour occurs 
only during episodes of anorexia are given the diagnosis anorexia nervosa, binge-
eating/purging type. A diagnosis of bulimia should only be given when all criteria for bulimia 
have been met for at least 3 months and when the individual no longer meets the full criteria 
for anorexia. This being said, it is important to note that crossover between anorexia and 
bulimia is also a common occurrence. According to one 7 year follow-up study performed by 
Eddy and his colleagues, 72.73% of participants with an intake diagnosis of anorexia 
experienced diagnostic crossover with 34.09% of those being from anorexia to bulimia. 
Notably, approximately half of the patients with anorexia who crossed over to bulimia did so 
in the course of progressing to partial or full recovery, whereas the other half who 
experienced crossover to bulimia were likely to cross back over into anorexia. Furthermore, 
they found that women with bulimia were unlikely to develop anorexia during follow-up 
(Eddy et al., 2008). This study clearly demonstrates the possible crossover that can occur 
between the two diseases in a single patient.  
 Sometimes patients may present with the classic bulimic symptom of binge-eating 
however, they may lack the other diagnostic criteria for bulimia. In such patients, a 
differential diagnosis of binge-eating disorder (BED) should be considered. Patients with this 
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disorder binge eat but do not engage in regular inappropriate compensatory behaviours 
(DSM-5). A supplementary difference that can be seen between the two conditions involves 
the BMI of the patients. According to one study performed by Striegel-Moore and her 
colleagues, obesity (BMI >30) was more commonly associated with BED than with bulimia 
(Striegel-Moore et al.,2001). Negative psychological and social problems are also associated 
with BED. However, comparisons of individuals with BED and individuals with bulimia 
have found that individuals with BED exhibit less comorbid psychopathology and report less 
subjective distress and better social adjustment than those with bulimia (Fichter, Quadflieg, & 
Brandl, 1993).   
 Major depressive disorder, with atypical features, is considered to be another possible 
differential diagnosis for bulimia. It is characterized by at least two weeks of low mood that 
is present across most situations and is accompanied by low self-esteem, low energy, and loss 
of interest in enjoyable activities. Overeating is common in major depressive disorder, with 
atypical features, but individuals do not engage in inappropriate compensatory behaviours 
and do not exhibit excessive concern with body shape and weight (DSM-5). Patients with 
bulimia can exhibit symptoms similar to those seen in major depressive disorder. According 
to Dr. Casper, symptoms of depression and anxiety are commonly reported by bulimia 
patients who apply to speciality clinics, with 56% of women scoring 20 on the Beck 
Depression Inventory (BDI) (Casper, 1998). Comorbidity with mental disorders is actually 
common in individuals with bulimia, with most experiencing at least one other mental 
disorder and many experiencing multiple comorbidities (DSM-5). Therefore, it is important 
to note that if criteria are met for another condition both diagnoses should be given. 
 There are numerous other conditions where a patient can exhibit a disturbed eating 
behaviour. Kleine-Levin syndrome, a condition that is characterized by persistent episodic 
hypersomnia and cognitive or mood changes, can also present with hyperphagia. Binge-
16 
 
eating behaviour is also included in the impulsive behaviour criterion that is part of the 
definition of borderline personality disorder (DSM-5).What these other conditions do share in 
common is the lack of over concern with body shape and weight. 
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8. TREATMENT 
 
 
 As with any other psychiatric condition, a full assessment is one of the essential 
things to do before deciding on any treatment. This assessment includes a full psychiatric 
history, a full medical history, and a physical examination. At this point, routine and focused 
blood tests can also be performed, as well as an ECG. Patients with bulimia are usually 
managed as outpatients. Admissions are only for suicidality, physical problems, extreme 
refractory cases, or if pregnant (Semple & Smyth, 2009). Treatment primarily consists of 
pharmacotherapy and psychotherapy. According to the oxford handbook of psychiatry, 
combined approaches improve the outcome.  
 
 
Pharmacotherapy:  
 
-SSRIs- 
 
Fluoxetine  
 
The gold standard for bulimia treatment is considered to be 60mg of fluoxetine. It has 
been successful in reducing binge/purge frequency as well as eating disorder cognitions 
including weight concern, food preoccupation, restraint, and drive for thinness. In addition, it 
has shown to be well tolerated and superior to 20mg of fluoxetine (Brown & Keel, 2012). 
Therefore, fluoxetine is very effective in the acute management of bulimia. One study, 
performed by Romano and colleagues, examined whether continuation of pharmacotherapy 
with fluoxetine provided protection from relapse. The results of this study demonstrated that 
fluoxetine-treated patients exhibited a longer time to relapse than placebo-treated patients. 
More specifically, 52 weeks of 60mg fluoxetine significantly reduced relapse rate compared 
to placebo (33% vs. 51%, respectively) and increased time to relapse (i.e., was associated 
with sustained remission) (Romano et al., 2002). On the other hand, there has been mixed 
support for fluoxetine’s efficacy in reducing depressive symptoms in patients with bulimia. 
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Some studies found no difference between fluoxetine and placebo while others favoured 
fluoxetine (Brown & Keel, 2012). Overall however, for fluoxetine a category grade A 
evidence exists with a good risk-benefit ratio (Aigner et al., 2011). Therefore, although 
fluoxetine is very effective in reducing binge/purge frequency and eating-related symptoms, 
it is not that efficacious for reducing depressive symptoms.  
 
Fluvoxamine 
 
 Fluvoxamine functions both as an SSRI and as a σ1 receptor agonist. It is primarily 
used in the treatment of obsessive-compulsive disorder (OCD) and as a result, relatively few 
studies have focused on its use in bulimia. However, of those studies that did, fluvoxamine 
has been shown to be superior to placebo for reducing binge/purge frequency (Brown & 
Keel, 2012). More specifically, 200mg of fluvoxamine/ day, administered for 12 weeks, 
showed a statistically significant reduction in the number of binge-eating crises and purging 
episodes compared with placebo (Milano et al., 2005). Not only is fluvoxamine effective for 
acute bulimia, it has also been shown to prevent relapse as well. According to one study 
performed by Fichter and colleagues, the following scales showed fluvoxamine to have a 
significant effect in reducing the return of bulimic behaviour: (1) self-ratings: Eating Disorder 
Inventory (EDI)-bulimia, urges to binge in previous week and the number of actual binges in 
the previous week; (2) expert ratings: Psychiatric Status Rating Scales for Bulimia nervosa, 
Structured Interview for Anorexia and Bulimia nervosa (SIAB)-"total score," SIAB-subscale 
"fasting," and SIAB-subscale "vomiting" (Fichter et al., 1996). Therefore, fluoxetine is 
effective at controlling the binge/purge cycle as well as preventing relapses.  
  
Sertraline  
 
 Like the aforementioned drugs from the SSRI class, sertraline has also been shown to 
be effective in the treatment of bulimia. One study, performed by Sloan and colleagues, 
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showed significant reductions in eating disorder psychopathology, including the number of 
binges and purges per week, as well as significant reductions in depressive symptoms. In 
addition, participants did not experience significant weight gain or any other sertraline side 
effect assessed at the end of the trial compared with baseline (Sloan et al., 2003). In another 
study, conducted by Milano and colleagues, patients received sertraline 100 mg/day for 12 
weeks. Results showed that the group treated with sertraline had a statistically significant 
reduction in the number of binge eating crises and purging compared with the placebo group 
(Milano et al., 2004). Both of these studies confirm that sertraline is well tolerated and 
effective in reducing binge-eating crises and purging in patients with bulimia.  
 
-Tricyclic Antidepressants-  
 
Imipramine  
 
 Given that affective disturbances have been commonly associated with bulimia, early 
pharmacological treatments focused on tricyclic antidepressants (TCA) and showed efficacy 
in decreasing binge episodes compared to placebo (Brown & Keel, 2012). These medications, 
however, were associated with adverse side effects and thus, current pharmacotherapy no 
longer has them as first line treatment. Imipramine is a TCA of the dibenzazepine group. 
Although it is mainly used for major depression and enuresis, it has been shown to be 
effective in bulimia as well. In saying so, for tricyclic antidepressants a grade A evidence 
exists with a moderate-risk-benefit ratio (Aigner et al., 2011). According to one placebo 
controlled double blind study with imipramine in 22 patients with bulimia, imipramine was 
associated with significant reduction in binge eating and other measures of eating behaviour 
(Pope at al., 1983). On the other hand, other studies did not find the same results. According 
to Mitchell and colleagues, who performed a 12 week comparison study of imipramine and 
structured group psychotherapy, imipramine did not significantly improve eating behaviour 
over placebo, but reduced symptoms of depression and anxiety (Mitchell et al., 1990). 
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Therefore, although this drug is said to be effective in the majority of articles, there are others 
that state otherwise.  
 
-Anticonvulsants-  
 
Topiramate  
 
 Although topiramate is an anticonvulsant drug, it has interestingly enough also been 
approved by the FDA, in combination with phentermine, for weight loss. In addition to these 
indications, topiramate is also used in the treatment of bulimia and a grade 2 recommendation 
can be made (Aigner et al., 2011). According to one 10 week randomized, double blind, 
placebo controlled trial performed by Hoopes and colleagues, there was significant reduction 
in binge and purge symptoms seen in bulimic patients taking topiramate (Hoopes et al., 
2003). When Hedges and colleagues analysed this same sample, they also found that there 
was a significant reduction in other behavioural and psychopathological dimensions (Hedges 
et al., 2003). On the other hand, side effects of this drug have also been reported. In one study 
performed by Nickel and colleagues, patients receiving topiramate treatment were noted to 
also exhibit sedation, dizziness, headaches, and parasthesia, but there were no psychotic 
symptoms, nor serious side effects (Nickel et al., 2005). Therefore, although it may be 
effective, side effects can limit its use.   
 
 
Psychotherapy: 
 
-Cognitive behavioural therapy- 
 
Cognitive behavioural therapy (CBT) is a goal-oriented treatment modality that takes 
a practical approach to problem-solving. The main goal in CBT is to change the patterns of 
thinking and behaviour that are behind the patient’s difficulties. In the past five years, 
numerous articles have emerged that reinforce and extend the place of CBT as the leading 
approach in the treatment of eating disorders in adults (Waller, 2016). In bulimia specifically, 
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CBT is delivered in 16-20 sessions over 4-5 months and has received an “A” grade by the 
National Institute for Clinical Excellence (NICE) in the UK (Brown & Keel, 2012). The 
efficacy of this mode of treatment may be due to the well-developed symptom maintenance 
models for bulimia. Within the CBT model, binge eating and subsequent purging are 
consequences of extreme dietary restraint; thus, reducing dietary restraint by regularizing the 
patient’s meal pattern results in reductions in binge/purge frequency (Brown & Keel, 2012).  
According to Brown and Keel, there is less support for CBT improving secondary 
symptoms such as depression, social adjustment, self-esteem, interpersonal problems, and 
global psychiatric symptoms, beyond alternative treatments (Brown & Keel, 2012). On the 
other hand, the National Collaborating Centre for Mental Health (UK) states that there is 
strong evidence suggesting that there is a clinically significant difference between CBT and 
wait-list control with CBT being superior with regard to the mean depression score by the 
end of treatment (N = 3; n = 87; Random Effects SMD = −1.19; 95 per cent CI, −1.99 to 
−0.39). Further, a meta-analysis of treatments in bulimia found that CBT had larger effect 
sizes than medication for reducing binge frequency (CBT = 1.28, medication = 0.66), purge 
frequency (CBT = 1.22, medication = 0.39), disordered eating attitudes (CBT = 1.35, 
medication = 0.71), and depression (CBT = 1.31, medication = 0.73) (Brown & Keel, 2012). 
In conclusion, the weight of evidence as measured in terms of the strength and consistency of 
the findings and the number of relevant studies indicates that CBT (delivered on a one-to-one 
basis) is the most effective treatment for bulimia (National Collaborating Centre for Mental 
Health (UK)).  
 
-Family- based treatment-  
 
 Family- based treatment (FBT) for bulimia is adapted from FBT for anorexia and like 
its predecessor, is designed for adolescents. The term FBT specifically refers to the treatment 
modality developed at the Maudsley Hospital in London, England. According to the 
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American society of clinical psychology, this treatment modality consists of 3 phases. In the 
first phase, parents are responsible for helping their child re-establish a healthy eating pattern 
and prevent binge eating and purging episodes. The second phase begins once the acute 
symptoms have abated and a regular pattern of eating is established. At this time, control over 
eating is returned to the adolescent. Finally, in the third phase of treatment, issues of family 
structure and normal adolescent development are addressed. According to one study 
performed by Le Grange and colleagues, 20 sessions of family based therapy was superior to 
supportive psychotherapy on remission rates, and reductions in compensatory behaviours, 
dietary restraint, and eating, weight, and shape concerns (Le Grange, 2007) In addition, it 
should be noted that FBT has the more immediate benefit when compared directly with CBT 
for adolescents with bulimia, although it was not statistically superior to CBT at follow-up 
(Waller, 2016). Therefore, in the adolescent age group, CBT should be considered as an 
alternative that can be used only where FBT is not possible or indicated or where FBT has 
failed to be effective (Waller, 2016). 
 
-Interpersonal psychotherapy-   
 
 Interpersonal psychotherapy (IPT) is a type therapy that focuses on resolving 
interpersonal problems and on symptomatic recovery. It is a treatment alliance in which the 
therapist empathically engages the patient, helps the patient to feel understood, arouses affect, 
presents a clear rationale and treatment ritual, and yields success experiences (Markowitz & 
Weissman, 2004). According to the National Collaborating Centre for Mental Health (UK), 
IPT appears to be as effective as CBT at eight to 12-month post-treatment follow-up (i.e. one 
year after starting treatment). Prior to this time, CBT is more effective. As a result, ITP 
should be considered as an alternative to CBT. In addition, there is evidence suggesting that it 
is unlikely there is a clinically significant difference between CBT and IPT on mean 
frequency of binge eating by the end of treatment (N = 2; n = 262; SMD = −0.24; 95 per cent 
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CI, −0.48 to 0.01) (NICE). According to another study, at 1-year and 5-year follow up, IPT 
was as effective as CBT in facilitating remission and ameliorating secondary symptoms, 
including general psychiatric symptoms, social adjustment, and depressive symptoms (Brown 
& Keel, 2012).Therefore, IPT appears to be effective for achieving long-term remission, yet 
CBT facilitates remission more rapidly. 
 
 
Combining pharmacotherapy with psychotherapy: 
 
 Given the effectiveness of psychotherapy and also pharmacotherapy as treatments for 
bulimia it is acceptable to assume that a combination of these two modalities would produce 
even better results. According to Hall and colleagues, a Cochrane review of 17 RCTs 
involving 827 patients reported three separate meta-analyses that evaluated the comparative 
effectiveness of antidepressants and psychotherapy for bulimia. The outcome for 
effectiveness was full remission of bulimic symptoms (binge and purge episodes). Although 
psychotherapy alone was more effective than antidepressants alone, combination therapy was 
superior to either option alone (Hall et al., 2008). On the other hand, according to Brown and 
Keel, no differences have emerged between combined treatments and CBT alone for reducing 
binge/purge frequency. However, there has been some evidence that the addition of 
antidepressant medication may improve depressive symptoms above CBT alone (Brown & 
Keel, 2012). Other studies have suggested this as well. According to a study performed by 
Goldbloom and colleagues, there is limited support for the superiority of the fluoxetine- CBT 
condition over fluoxetine and no statistically significant evidence that the combination of 
pharmacotherapy and psychotherapy is superior to psychotherapy alone (Goldbloom et al., 
1997). Yet, Goldbloom also states that the results of the study are compatible with those of 
Agras et al. (1992) and according to Agras et al. there is superiority of the combined method 
over a number of outcome parameters (Goldbloom et al., 1997). Therefore, when it comes to 
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the effectiveness of combining pharmacotherapy and psychotherapy there seems to be a lot of 
discrepancies among literature. While some authors and studies suggest it to be more 
effective than either modality alone, other studies suggest otherwise.  
 
 
Light therapy:  
 
There are conflicting views about light therapy and its effectiveness in treating 
bulimia. In one study conducted by Lam and colleagues, bright white light (BWL) (10.000 
lux for 30 min/day) or dim red light (DRL) (500 lux 30 min/day) was administered to17 
female patients with bulimia. The results of the study showed that BWL therapy is an 
effective short term treatment for both mood and eating disturbances associated with bulimia 
with great efficacy, if there is a seasonal pattern (Lam at al. 1994). In a similar manner, a 
double blind placebo controlled study with the objective to determine the effects of winter 
bright light therapy on binge and purge frequencies and depressive symptoms in subjects with 
bulimia, found that the mean binge frequency decreased significantly more from baseline to 
the end of treatment for the bright light group than for the placebo group (Braun et al., 1999). 
On the other hand, other studies did not show such positive results with light therapy. In a 
study performed by Blouin and colleagues, no effect of light therapy was found on the 
frequency, size, or content of binge-eating episodes. However, subjects in the bright light 
condition showed a significant improvement in depressed mood during light exposure, as 
measured by both the Beck Depression Inventory (BDI) and the Structured Interview Guide 
for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-
SAD). Yet, there was a return to pre-treatment levels of depression after withdrawal of light 
exposure (Blouin et al., 1996). What is constant in all of these studies however, is that light 
therapy is very effective in the treatment of mood.  
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9. PROGNOSIS 
 
 
 The prognosis of patients who have bulimia is generally considered to be good. 
However, if there is significant issues of low self-esteem or evidence of a sever personality 
disorder the prognosis can be tremendously affected (Semple & Smyth, 2009). In a similar 
manner, duration of illness also affects the prognosis. According to one study performed at 
the Department of Psychology at Louisiana State University, good outcome in bulimia and 
subthreshold bulimia was associated with a shorter duration of illness, which was defined as 
the time between onset of symptoms and first treatment intervention. If participants were 
initially treated within the first few years of the illness, the probability of recovery was above 
80%. On the other hand, if they were initially treated 15 years or more after the onset of 
illness, the probability of recovery fell below 20% (Rheas et al., 1999). This study indicates 
the importance of early identification and treatment of patients with bulimia.    
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